{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:12:32Z","timestamp":1761952352171,"version":"build-2065373602"},"reference-count":0,"publisher":"Association of Basic Medical Sciences of FBIH","issue":"2","license":[{"start":{"date-parts":[[2006,5,20]],"date-time":"2006-05-20T00:00:00Z","timestamp":1148083200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>Strict\u00a0therapy\u00a0protocol, which would be used universally for certain morphological forms of\u00a0primary\u00a0nephrotic syndrome, does not exist. The aim of the study was to show the effects of used\u00a0therapy\u00a0protocol in\u00a0treatment\u00a0of\u00a0primary\u00a0nephrotic syndrome\u00a0at the Institute of Nephrology, Clinical Center University of Sarajevo in period of 2000-2005. The retrospective analysis covered 48 patients (17 women and 31 men) with idiopathic\u00a0nephrotic syndrome, where pathomorphological changes were proved by kidney biopsy. Minimal change disease was confirmed with 6 (12.5%) patients. All patients were initially treated with corticosteroids with dose of 1 mg\/kg of body weight. Five patients were in the group of\u00a0primary\u00a0responders (83.3%) with long term total remission, and 1 patient (16.6%) was a\u00a0primary\u00a0responder with 3 relapses in 8 months with a\u00a0therapy\u00a0of corticosteroids and bolus of cyclophosphamide. Diffuse mesangial proliferative glomerulonephritis was shown in 13 patients (27.1%). Seven patients from this group were treated with corticosteroid\u00a0therapy\u00a0(1 mg\/kg of body weight for 4 weeks, followed by 0.5 mg\/ kg of body weight until therapeutical response was achieved, and finally gradual exclusion of\u00a0therapy\u00a0after eight weeks in responsive patients). Six patients were treated with corticosteroids and one-month of bolus cyclophosphamide during half of year (10-5 mg\/kg of body weight). Total remission was achieved in 37,9% of the patients. The IgA nephropathy presented with the\u00a0nephrotic syndrome\u00a0was shown in 10.4% (5) of the patients. Three patients from this group were treated with corticosteroid\u00a0therapy\u00a0(1 mg\/kg of body weight for 4 weeks, followed by 0,5 mg\/ kg of body weight until therapeutical response was achieved, and finally gradual exclusion of\u00a0therapy\u00a0after eight weeks in responsive patients) and.2 patients with corticosteroids and cyclophosphamide (1.5 mg\/kg of body weight) during 6 months. Complete remission of\u00a0nephrotic syndrome\u00a0from this pathomorphological category was achieved in 2 patients. Membranoproliferative glomerulonephritis was shown in 6 patients (12.5%). All were treated with corticosteroids plus bolus of cyclophosphamide. Partial remission was achieved in one patient. Membranous glomerulonephritis was confirmed in 18 patients (37.5 %). Combined\u00a0therapy\u00a0of corticosteroids and bolus of cyclophosphamide was used in 7\/18 patients, in 2\/18 patients\u00a0therapy\u00a0of corticosteroids and per os cyclophosphamide (2 mg\/kg of body weight) and in 9\/18 patients cyclosporine\u00a0therapy\u00a0(3 mg\/kg of body weight). Complete remission was achieved in 38.8% of the patients. A high percentage of achieved remissions of\u00a0primary\u00a0nephrotic syndrome\u00a0in\u00a0adults\u00a0shows the efficiency of immunomodulating\u00a0therapy\u00a0used. Membranoproliferative glomerulonephritis still remains a\u00a0therapy\u00a0problem.<\/jats:p>","DOI":"10.17305\/bjbms.2006.3166","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T19:17:01Z","timestamp":1527707821000},"page":"16-20","source":"Crossref","is-referenced-by-count":1,"title":["Treatment aspects of primary nephrotic syndrome in adults"],"prefix":"10.17305","volume":"6","author":[{"given":"Senija","family":"Ra\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snje\u017eana","family":"Un\u010danin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasminka","family":"D\u017eemid\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenana","family":"Aganovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira","family":"Srna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismar","family":"Ra\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6922","published-online":{"date-parts":[[2006,5,20]]},"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/3166\/866","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/3166\/866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:08:06Z","timestamp":1761952086000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/3166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,20]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,18]]}},"URL":"https:\/\/doi.org\/10.17305\/bjbms.2006.3166","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"type":"electronic","value":"2831-090X"},{"type":"print","value":"2831-0896"}],"subject":[],"published":{"date-parts":[[2006,5,20]]}}}